Much like TNBC, the role of AR while in the management of estrogen receptor-favourable (ER+) breast cancer is a place of Lively analysis. AR is expressed in around ninety% of ER+ tumors and preclinical information indicates that AR expression is connected to resistance to both of those tamoxifen and